Cibus Stock Earnings Reports

Cibus reports commercial momentum in Q1 2026 driven by progress across its rice royalty program and Sustainable Ingredients business. The company raised approximately $37 million in gross proceeds from two public offerings and says this capital, along with cost reductions, funds operations into late Q1 2027 while targeting annual net cash usage of ~$30 million or less for 2026. Key commercial milestones: delivery of gene-edited herbicide-tolerant rice materials to Latin American partner Interoc with a nonbinding LOI targeting initial LATAM entry (Ecuador, Colombia) in 2027 and phased expansion thereafter; U.S. rice launch timing pushed from 2028 to 2029 due to herbicide (clethodim) registration timing with chemistry partner Albaugh. Sustainable Ingredients is moving toward commercial scale with additional customer payments and expected scale-up orders in H2 2026 (biofragrances and crop-based oleic oils), representing a near-term revenue bridge. Scientific updates highlight an order-of-magnitude improvement in rice editing efficiency, AI/ML integration, single-cell regeneration in wheat, and advancing nutrient-use-efficiency collaborations. Regulatory developments are a tailwind (17 positive USDA-APHIS determinations, Latin American equivalence rulings, EU New Genomic Techniques progress). Management emphasizes execution, advancing partner negotiations, getting materials into seed systems, and converting the pipeline into revenue.